Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
Antimicrobial resistance AMR is an emerging global threat to human health, and intensive care units (ICUs) are a 'hot spot' for the emergence and diffusion of multidrug-resistant (MDR) bacteria. ICU-acquired colonization and infection with MDR bacteria (ICU-MDR-col and ICU-MDR-inf, respectively) have been associated wi
| Condition(s) | Critically-ill Patients |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Antimicrobial resistance AMR is an emerging global threat to human health, and intensive care units (ICUs) are a 'hot spot' for the emergence and diffusion of multidrug-resistant (MDR) bacteria. ICU-acquired colonization and infection with MDR bacteria (ICU-MDR-col and ICU-MDR-inf, respectively) have been associated with higher ICU length-of-stay, duration of invasive mechanical ventilation and mortality. Immunocompromised patients account for an increasing proportion of ICU patients, and they are particularly prone to ICU-acquired infections, a significant proportion of which are caused by MDR pathogens. Recently, in a prospective multicenter study in France (CIMDREA, 8 ICUs, 750 patients), we found that immunocompromised patients had a lower cumulative incidence of ICU-MRD-col, but not I |
| Who can participate | Inclusion Criteria: 1. Patients aged 18 and over. 2. Admitted to intensive care and whose length of stay is greater than 48 hours (inclusion is at the 48th hour after admission). 3. Immunocompetent OR immunocompromised patients according to one of the following criteria: 1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care); 2. Hematological malignancies under treatment or in remission for less than 5 years (including hematological malignancies diagnosed during hospitalization in intensive care); 3. Neutropenia \< 0.7 G/L for ≥ 7 days; 4. Solid organ transplants; 5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \> 10 mg/day) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Hospital, Lille |
| Locations | Lille, France |
| Start date | 2025-03-19 |
| NCT ID | NCT06652126 |
| Official listing | https://clinicaltrials.gov/study/NCT06652126 |